NATALIE DEGGANS: Open Payments
NPI 1164629440 · COVINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$645 in 34 payments from 15 companies in 2025. Trend: 2023 $503 · 2024 $307 · 2025 $645
Food & beverage: $573Education: $72
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 10 | $153 |
| Actelion Pharmaceuticals US, Inc. | 3 | $105 |
| Novo Nordisk Inc | 4 | $81 |
| PFIZER INC. | 2 | $43 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
| Amgen Inc. | 2 | $34 |
| Merck Sharp & Dohme LLC | 2 | $31 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $31 |
| Boston Scientific Corporation | 1 | $26 |
| Contego Medical, Inc | 1 | $22 |
Products named: CAMZYOS, Wegovy, OPSUMIT, ELIQUIS, LEQVIO, REPATHA, VERQUVO, Kerendia.
Industry payments across LA — which companies pay providers there.
